【2024年最新】オンカジ入金不要ボーナスおすすめ26選👑 ...

About NCVC About NCVC About NCVC TOP The Center's Mission Organization History of the NCVC Location News Releases Close Hospital Hospital Hospital TOP About the Hospital The Group of Treatment Close Research Institute Research Institute Research Institute TOP About the Research Institute Departments Office for the Promotion of Diversity and Inclusion Research Institute and Open Innovation Center Brochure Close Open Innovation Center Open Innovation Center Open Innovation Center TOP Research Institute and Open Innovation Center Brochure Close Pamphlet National Cerebral and CardiovascularCenter Hospital Res. Inst. OICOpen Innovation Center Access Background White Black Japanese Access Menu National Cerebral and Cardiovascular Center TOP Open Innovation Center Omics Research Center (ORC) Open Innovation Center Omics Research Center (ORC) MemberDirectorOsamu YamaguchiDeputy DirectorAtsushi TakahashiLaboratory ChiefManabu ShiraiNaoyuki SugiyamaStaff ScientistMorikatsu Yoshida ResearchTo Decipher Unexplored Molecular Basis of Cardiovascular Diseases by Means of Multi-Omics ApproachesIdentification of novel biological, genetic, and clinical markers is essential for the "Precision Medicine"that achieves early diagnosis and prevention of patients at risk. By implementing multi-omics approaches including comprehensive genetic, genomic, proteomic, transcriptomic, and even physiomics analyses, and taking advantage of international collaborations, we aim at interrogating unexplored molecular mechanisms underlying several cardiovascular diseases, such as inherited lethal arrhythmia, common arrhythmia, cardiomyopathy, heart failure, and vascular diseases.Global collaboration of the comprehensive genetic and genomic studies for arrhythmiasMulti-omics study of dilated cardiomyopathyDevelopment of high throughput screening technology to functionally validate ion channel VUSs responsible for lethal arrhythmiaEpigenetic study of congestive heart failureDevelopment of novel therapy for cardiovascular diseases using high throughput screening systemPublicationYamazaki M, Makita N, Tsuji Y et al. Rotors anchored by refractory islands drive torsades de pointes in an experimental model of electrical storm. Heart Rhythm (2021). doi:10.1016/j.hrthm.2021.10.012Masaki T, Shirai M, Nakaoka Y et al. Aryl hydrocarbon receptor is essential for the pathogenesis of pulmonary arterial hypertension. Proc Natl Acad Sci USA 118 (2021). doi:10.1073/pnas.2023899118Kozek K, Ishikawa T, Makita N, Kroncke B.M. et al. Estimating the Posttest Probability of Long QT Syndrome Diagnosis for Rare KCNH2 Variants. Circ Genom Precis Med 14, e003289 (2021). doi:10.1161/CIRCGEN.120.003289Ishikawa T, Makita N et al. Functionally validated SCN5A variants allow interpretation of pathogenicity and prediction of lethal events in Brugada syndrome. Eur Heart J 42, 2854-2863 (2021). doi:10.1093/eurheartj/ehab254Wijeyeratne YD, Ishikawa T, Makita N, Behr ER　et al. SCN5A Mutation Type and a Genetic Risk Score Associate Variably With Brugada Syndrome Phenotype in SCN5A Families. Circ Genom Precis Med 13, e002911 (2020). doi:10.1161/CIRCGEN.120.002911Otani K, Minamino N, Kangawa K. et al. Deficiency of Cardiac Natriuretic Peptide Signaling Promotes Peripartum Cardiomyopathy-Like Remodeling in the Mouse Heart. Circulation 141, 571-588 (2020). doi:10.1161/CIRCULATIONAHA.119.039761Lahrouchi N, Ishikawa T, Makita N, Bezzina CR　et al. Transethnic Genome-Wide Association Study Provides Insights in the Genetic Architecture and Heritability of Long QT Syndrome. Circulation 142, 324-338 (2020). doi:10.1161/CIRCULATIONAHA.120.045956Ishikawa T, Makita N et al. Cardiac Emerinopathy: A Nonsyndromic Nuclear Envelopathy With Increased Risk of Thromboembolic Stroke Due to Progressive Atrial Standstill and Left Ventricular Noncompaction. Circ Arrhythm Electrophysiol 13, e008712 (2020). doi:10.1161/ CIRCEP.120.008712Takahama H, Minamino N, Izumi C. Plasma soluble neprilysin levels are unchanged during recovery after decompensation of heart failure: a matter of the magnitude of the changes in systemic haemodynamics? Eur Heart J 39, 3472-3473 (2018). doi:10.1093/eurheartj/ ehy454Miyazaki T, Minamino N, Mochizuki N et al. A New Secretory Peptide of Natriuretic Peptide Family, Osteocrin, Suppresses the Progression of Congestive Heart Failure After Myocardial Infarction. Circ Res 122, 742-751 (2018). doi:10.1161/CIRCRESAHA.117.312624Kanai Y, Minamino N, Inagaki N et al. Circulating osteocrin stimulates bone growth by limiting C-type natriuretic peptide clearance. J Clin Invest 127, 4136-4147 (2017). doi:10.1172/ JCI94912last updated：2024/04/09 (Corporate number:3120905003033) 6-1 Kishibe-Shimmachi, Suita, Osaka, 564-8565, Japan TEL：81-6-6170-1070 Access Copyright © National Cerebral and Cardiovascular Center All rights reserved. Site setting Font-size Normal Large Background White Black Japanese English